These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 11508675)

  • 1. Successful treatment of refractory esophageal Crohn's disease with infliximab.
    Fefferman DS; Shah SA; Alsahlil M; Gelrud A; Falchulk KR; Farrell RJ
    Dig Dis Sci; 2001 Aug; 46(8):1733-5. PubMed ID: 11508675
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab: how to use it in pediatric Crohn's disease.
    Ruemmele FM
    J Pediatr Gastroenterol Nutr; 2004 Jul; 39(1):12-4. PubMed ID: 15187774
    [No Abstract]   [Full Text] [Related]  

  • 3. Infliximab treatment for Crohn's disease.
    Conroy CA; Cattell R
    Postgrad Med J; 2001 Jul; 77(909):436-40. PubMed ID: 11423591
    [No Abstract]   [Full Text] [Related]  

  • 4. Esophageal Crohn's disease treated successfully with adalimumab.
    Kwan LY; Conklin JL; Papadakis KA
    Inflamm Bowel Dis; 2007 May; 13(5):639-40. PubMed ID: 17221856
    [No Abstract]   [Full Text] [Related]  

  • 5. [Recommendations for the use of infliximab (Remicade) in Crohn's disease. GETECCU 2001].
    Domènech E; Esteve-Comas M; Gomollón F; Hinojosa J; Obrador A; Panés J; Gassull MA;
    Gastroenterol Hepatol; 2002 Mar; 25(3):162-9. PubMed ID: 11864540
    [No Abstract]   [Full Text] [Related]  

  • 6. Infliximab (Remicade): the magic bullet for Crohn's disease?
    D'Haens G
    Dig Liver Dis; 2000 Nov; 32(8):653-6. PubMed ID: 11142571
    [No Abstract]   [Full Text] [Related]  

  • 7. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab (Remicade), a new biological treatment for Crohn's disease.
    D'Haens GR
    Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discussion on predictors of response to infliximab in patients with Crohn's disease.
    Hommes D
    Gastroenterology; 2003 Jun; 124(7):2002-3. PubMed ID: 12812196
    [No Abstract]   [Full Text] [Related]  

  • 10. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
    Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease].
    Holtmann M; Wanitschke R; Helisch A; Bartenstein P; Galle PR; Neurath M
    Z Gastroenterol; 2003 Jan; 41(1):11-7. PubMed ID: 12541166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumor necrosis factor-alpha inhibitor.
    Wagner TE; Huseby ES; Huseby JS
    Am J Med; 2002 Jan; 112(1):67-9. PubMed ID: 11812409
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for).
    Shanahan F
    Inflamm Bowel Dis; 2000 May; 6(2):137-9. PubMed ID: 10833074
    [No Abstract]   [Full Text] [Related]  

  • 14. Systemic amyloidosis with Crohn's disease treated with infliximab.
    Park YK; Han DS; Eun CS
    Inflamm Bowel Dis; 2008 Mar; 14(3):431-2. PubMed ID: 17932971
    [No Abstract]   [Full Text] [Related]  

  • 15. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J; Kucharzik T
    Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of oesophageal Crohn's disease by infliximab].
    Filippi J; Mambrini P; Arab K; Schneider SM; Hébuterne X
    Gastroenterol Clin Biol; 2005 Jan; 29(1):84-5. PubMed ID: 15738903
    [No Abstract]   [Full Text] [Related]  

  • 17. [Management and treatment of Crohn's disease. 2. Anti-cytokine therapy].
    Ito H
    Nihon Naika Gakkai Zasshi; 2009 Jan; 98(1):88-93. PubMed ID: 19338091
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease.
    Bell S; Kamm MA
    Lancet; 2000 Mar; 355(9207):858-60. PubMed ID: 10752696
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment-resistant lingual Crohn's disease disappears after infliximab.
    Brunner B; Hirschi C; Weimann R; Seibold F
    Scand J Gastroenterol; 2005 Oct; 40(10):1255-9. PubMed ID: 16265783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab.
    van Deventer SJ
    Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():3-8; discussion 38. PubMed ID: 10597333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.